Theriva™ biologics announces key progress in virage, an ongoing, multinational phase 2b trial of vcn-01 in combination with chemotherapy in pancreatic ductal adenocarcinoma

– initiated dosing at u.s. sites for virage – – second doses of intravenous vcn-01 administered to patients in spain and were well tolerated – – virage remains on track to complete enrollment in the first quarter of 2024 –

TOVX Ratings Summary

TOVX Quant Ranking